Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 11078257
Recombinant gram negative bacteria and methods of generating and utilizing same
granted -
US 11077175
Compositions and methods for treatment of homocystinuria
granted -
US 11076599
Antimicrobial coating comprising chalcogenide nano-particles capped by chitosan
granted -
US 11077108
Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition
granted -
US 11077241
Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combination with hyaluronic acid
granted -
US 11078491
Vaccines against Zika virus based on Zika structure proteins
granted -
US 11078266
Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of IL-3, and their use in a method to detect human IL-3
granted -
US 11078256
Methods and compositions for inhibiting cancer cell growth
granted -
US 11071787
Topiramate compositions and methods of making and using the same
granted -
US 11072594
Trioxolane agents
granted -
US 11072592
Small molecules that enable cartilage rejuvenation
granted -
US 11072600
Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
granted -
US 11072636
Peptide for inhibiting angiogenesis and use thereof
granted -
US 11072639
Bi-functional anti-tau polypeptides and use thereof
granted -
US 11072629
Reprogramming of cellular adhesion
granted -
US 11066666
Bioactive renal cells
granted -
US 11065280
Hepatocytes with high regenerative capacity for liver repair
granted -
US 11065264
Metal-olsalazine coordination polymers for medical applications
granted -
US 11066647
Pluripotent human adipose adult stem cells: isolation, characterization and clinical implications
granted -
US 11065347
Methods for the treatment of Danon disease and other disorders of autophagy
granted -
US 11065223
Antimicrobial compositions and uses thereof
granted -
US 11065285
Biomarkers and combination therapies using oncolytic virus and immunomodulation
granted -
US 11066481
Antibodies to coagulation factor XIa and uses thereof
granted -
US 11058645
Inhibition of respiratory complex III by ligands that interact with a regulatory switch
granted -
US 11061094
Simultaneous pH and oxygen weighted MRI contrast using multi-echo chemical exchange saturation transfer imaging (ME-CEST)
granted -
US 11059880
Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
granted -
US 11059796
Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORΞ³ and the treatment of disease
granted -
US 11059817
Potent antiviral pyrazolopyridine compounds
granted -
US 11060087
Synthetic promoters for high throughput screening and gene modulation
granted -
US 11058766
Universal vaccine platform
granted -
US 11059879
Chimeric antigen receptor molecules and uses thereof
granted -
US 11058802
Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
granted -
US 11058688
Imidazopiperazine inhibitors of transcription activating proteins
granted -
US 11054423
Antibody-mediated neutralization of ebolaviruses
granted -
US 11053310
Antibodies for the treatment of cancers
granted -
US 11052044
In situ lipid synthesis for protein reconstitution
granted -
US 11052060
Compounds and methods for treating autoimmunity
granted -
US 11052089
Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
granted -
US 11046709
Fused 1,4-diazepines as BET bromodomain inhibitors
granted -
US 11046730
Antimicrobial compositions
granted -
US 11046703
Small molecule MDM2 protein degraders
granted -
US 11046941
Methods of generating nucleic acid fragments
granted -
US 11046670
Piperazinyl norbenzomorphan compounds and methods for using the same
granted -
US 11045493
Synthetic melanin nanoparticles and uses thereof
granted -
US 11045443
Glutaminase inhibitor therapy
granted -
US 11045555
Pathogen-specific cargo delivery and diagnostic platform based on mesoporous silica nanoparticles
granted -
US 11045448
Piperidines as covalent menin inhibitors
granted -
US 11046755
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory